董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raj Mehra | 男 | Chairman, Chief Executive Officer, President & Interim Chief Financial Officer | 59 | 未披露 | 未持股 | 2019-03-28 |
| Robin L. Smith | 女 | Director | 53 | 未披露 | 未持股 | 2019-03-28 |
| Richard W. Pascoe | 男 | Director | 55 | 106.37万美元 | 未持股 | 2019-03-28 |
| Daniel J. O'Connor | 男 | Director | 53 | 未披露 | 未持股 | 2019-03-28 |
| Brian Lian | 男 | Director | 53 | 未披露 | 未持股 | 2019-03-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raj Mehra | 男 | Chairman, Chief Executive Officer, President & Interim Chief Financial Officer | 59 | 未披露 | 未持股 | 2019-03-28 |
董事简历
中英对照 | 中文 | 英文- Raj Mehra
-
Raj Mehra自2019年1月以来一直担任我们的总裁，首席执行官，临时首席财务官和董事会主席。在创立Seelos之前，Mehra博士在Auriga USA，LLC工作了9年，担任总经理，专注于全球梦百合公司的私人和公共股本投资。在加入Auriga之前，Mehra博士是纽约Bennett Lawrence Management，LLC的梦百合股票投资部门主管。他也曾创立并管理Weiss，Peck&Greer LLC的多空股票对冲基金。Mehra博士在Cowen Asset Management，LLC担任投资专业人员开始他的职业生涯。Mehra博士拥有纽约哥伦比亚大学（Columbia University）的M.S.，M.Phil.，博士，法学博士和工商管理硕士学位。他也是印度理工学院坎普尔分校（Indian Institute of Technology，Kanpur）的毕业生，在那里他在班上排名第一。
Raj Mehra has served on our board of directors since July 2021. Dr. Mehra has served as Seelos Therapeutics's President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board of Directors since January 2019. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC as a Managing Director focused on private and public equity investments in global healthcare companies. Prior to Auriga, Dr. Mehra was the sector head for healthcare equity investments at Bennett Lawrence Management, LLC in New York. He also founded and managed a long-short equity hedge fund at Weiss, Peck & Greer LLC. Dr. Mehra started his career as an investment professional at Cowen Asset Management, LLC. Dr. Mehra holds M.S., M.Phil., Ph.D., JD and MBA degrees from Columbia University in New York. He is also a graduate of Indian Institute of Technology, Kanpur, where he was ranked first in his class. - Raj Mehra自2019年1月以来一直担任我们的总裁，首席执行官，临时首席财务官和董事会主席。在创立Seelos之前，Mehra博士在Auriga USA，LLC工作了9年，担任总经理，专注于全球梦百合公司的私人和公共股本投资。在加入Auriga之前，Mehra博士是纽约Bennett Lawrence Management，LLC的梦百合股票投资部门主管。他也曾创立并管理Weiss，Peck&Greer LLC的多空股票对冲基金。Mehra博士在Cowen Asset Management，LLC担任投资专业人员开始他的职业生涯。Mehra博士拥有纽约哥伦比亚大学（Columbia University）的M.S.，M.Phil.，博士，法学博士和工商管理硕士学位。他也是印度理工学院坎普尔分校（Indian Institute of Technology，Kanpur）的毕业生，在那里他在班上排名第一。
- Raj Mehra has served on our board of directors since July 2021. Dr. Mehra has served as Seelos Therapeutics's President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board of Directors since January 2019. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC as a Managing Director focused on private and public equity investments in global healthcare companies. Prior to Auriga, Dr. Mehra was the sector head for healthcare equity investments at Bennett Lawrence Management, LLC in New York. He also founded and managed a long-short equity hedge fund at Weiss, Peck & Greer LLC. Dr. Mehra started his career as an investment professional at Cowen Asset Management, LLC. Dr. Mehra holds M.S., M.Phil., Ph.D., JD and MBA degrees from Columbia University in New York. He is also a graduate of Indian Institute of Technology, Kanpur, where he was ranked first in his class.
- Robin L. Smith
-
Robin L. Smith，她是医学博士。2005年9月，她加入Western Acquisition Ventures Corp.，担任咨询委员会主席并从2006年6月2日起，担任NeoStem的首席执行官和董事会主席。她的专长为商业发展和医学，在许多医疗企业和保健实体担任过主席和董事会水平的职位，有广泛而丰富的经验。在她的领导下，NeoStem成功地完成了5次收购、1次转让并将研发、商业单元扩张和战略交易增长了1.8亿美元。NeoStem连续两年成为Tri-State地区的第一名、在Deloitte's 2013 Technology Fast 500中排名11、北美500家最快发展的技术、媒体、通信、生命科学和清洁技术公司之一。2010年，NeoStem获得New Economy"Best Stem Cell Company"奖。
Robin L. Smith, MD, MBA, a Director, is a business leader, entrepreneur, medical doctor, and philanthropist uniquely positioned to assist public companies and health care systems to advance and be successful in the rapidly evolving health care industry. She is a trailblazer in the fields of regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations driving interest and growth.From 2006 until 2015 Dr. Smith was chairman and chief executive officer of the NeoStem, Inc. NASDAQ: NBS, where she pioneered the company's innovative business model combining proprietary cell therapy development with successful contract development and manufacturing organization that was sold to Hitachi, Ltd. (TYO: 6501) at 8x the price at which it had been acquired. During her 9 years of tenure, the company completed five acquisitions, one divestiture and won an array of industry awards and received business recognition including a first-place ranking in the tri-state area (two years in a row), and eleventh place nationally, on Deloitte's Technology Fast 500 and Frost & Sullivan's North American Cell Therapeutics Technology Innovation Leadership Award. In 2015 Dr. Smith was asked to become chair of the board of directors of Mynd Analytics, Inc. (NASDAQ: MYND) and successfully turn the business around through acquisitions and divestitures and brought liquidity to investors. In 2017 she founded Spiritus Therapeutics, Inc., a company in the exosome therapeutic area.Dr. Smith has extensive experience serving on the boards of directors and board committees, including, audit, nominating and governance, compensation and science and technology committees, of multiple public companies and private companies. She serves as a director of: Sorrento Therapeutics, Inc. (NASDAQ: SRNE); Celularity, Inc. (soon to de-SPAC with NASDAQ: GXGX); Vicinity, Inc.; and, Spiritus Therapeutics, Inc. Dr. Smith has also served on the board of ServiceSource International, Inc. (NASDAQ: SREV), of Seelos Therapeutics, Inc. (NASDAQ: SEEL), Rockwell Medical, Inc. (NASDAQ: RMTI), and BioXcel Corp.Dr. Smith co-authored Cells Are the New Cure -2017 and The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life -2013 She has also been widely recognized for her leadership in health care and as a female entrepreneur. Most recently, Dr. Smith received the Regenerative Medicine Foundation (RMF) 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy in 2019 and the 2018 HEALinc Future Health Humanitarian Award, the Business Intelligence Group's Woman of the Year Award in 2018 and the 2018 Gold StevieAward for Woman of the Year - Government or Non-Profit. In May 2016 Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. In May 2017 she was awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library.Dr. Smith is also active in many nonprofit organizations. She is the founder, president and chairperson of the board of the Cura Foundation, a charitable organization, and a member, serves on the board of overseers of the New York University Langone Medical Center and on the board of trustees of Sanford Health. She currently serves on the board of Alliance for Cell Therapy and served on the board of the Alliance for Regenerative Medicine (ARM) Foundation, Unite to Prevent Cancer (UTPC) Foundation now OPA and on the board of trustees of the New York University Langone Medical Center and was chairperson of board of directors of the New York University Hospital for Joint Diseases.Dr. Smith received her B.A. degree from Yale University and her M.D. degree from the Yale School of Medicine. Dr. Smith holds an M.B.A. degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019 Dr. Smith received an honorary doctor of science degree from Thomas Jefferson Medical College. - Robin L. Smith，她是医学博士。2005年9月，她加入Western Acquisition Ventures Corp.，担任咨询委员会主席并从2006年6月2日起，担任NeoStem的首席执行官和董事会主席。她的专长为商业发展和医学，在许多医疗企业和保健实体担任过主席和董事会水平的职位，有广泛而丰富的经验。在她的领导下，NeoStem成功地完成了5次收购、1次转让并将研发、商业单元扩张和战略交易增长了1.8亿美元。NeoStem连续两年成为Tri-State地区的第一名、在Deloitte's 2013 Technology Fast 500中排名11、北美500家最快发展的技术、媒体、通信、生命科学和清洁技术公司之一。2010年，NeoStem获得New Economy"Best Stem Cell Company"奖。
- Robin L. Smith, MD, MBA, a Director, is a business leader, entrepreneur, medical doctor, and philanthropist uniquely positioned to assist public companies and health care systems to advance and be successful in the rapidly evolving health care industry. She is a trailblazer in the fields of regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations driving interest and growth.From 2006 until 2015 Dr. Smith was chairman and chief executive officer of the NeoStem, Inc. NASDAQ: NBS, where she pioneered the company's innovative business model combining proprietary cell therapy development with successful contract development and manufacturing organization that was sold to Hitachi, Ltd. (TYO: 6501) at 8x the price at which it had been acquired. During her 9 years of tenure, the company completed five acquisitions, one divestiture and won an array of industry awards and received business recognition including a first-place ranking in the tri-state area (two years in a row), and eleventh place nationally, on Deloitte's Technology Fast 500 and Frost & Sullivan's North American Cell Therapeutics Technology Innovation Leadership Award. In 2015 Dr. Smith was asked to become chair of the board of directors of Mynd Analytics, Inc. (NASDAQ: MYND) and successfully turn the business around through acquisitions and divestitures and brought liquidity to investors. In 2017 she founded Spiritus Therapeutics, Inc., a company in the exosome therapeutic area.Dr. Smith has extensive experience serving on the boards of directors and board committees, including, audit, nominating and governance, compensation and science and technology committees, of multiple public companies and private companies. She serves as a director of: Sorrento Therapeutics, Inc. (NASDAQ: SRNE); Celularity, Inc. (soon to de-SPAC with NASDAQ: GXGX); Vicinity, Inc.; and, Spiritus Therapeutics, Inc. Dr. Smith has also served on the board of ServiceSource International, Inc. (NASDAQ: SREV), of Seelos Therapeutics, Inc. (NASDAQ: SEEL), Rockwell Medical, Inc. (NASDAQ: RMTI), and BioXcel Corp.Dr. Smith co-authored Cells Are the New Cure -2017 and The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life -2013 She has also been widely recognized for her leadership in health care and as a female entrepreneur. Most recently, Dr. Smith received the Regenerative Medicine Foundation (RMF) 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy in 2019 and the 2018 HEALinc Future Health Humanitarian Award, the Business Intelligence Group's Woman of the Year Award in 2018 and the 2018 Gold StevieAward for Woman of the Year - Government or Non-Profit. In May 2016 Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. In May 2017 she was awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library.Dr. Smith is also active in many nonprofit organizations. She is the founder, president and chairperson of the board of the Cura Foundation, a charitable organization, and a member, serves on the board of overseers of the New York University Langone Medical Center and on the board of trustees of Sanford Health. She currently serves on the board of Alliance for Cell Therapy and served on the board of the Alliance for Regenerative Medicine (ARM) Foundation, Unite to Prevent Cancer (UTPC) Foundation now OPA and on the board of trustees of the New York University Langone Medical Center and was chairperson of board of directors of the New York University Hospital for Joint Diseases.Dr. Smith received her B.A. degree from Yale University and her M.D. degree from the Yale School of Medicine. Dr. Smith holds an M.B.A. degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019 Dr. Smith received an honorary doctor of science degree from Thomas Jefferson Medical College.
- Richard W. Pascoe
-
Richard W. Pascoe，Pharmaceuticals收购。加入Somaxon之前，他是新兴的肿瘤制药公司ARIAD Pharmaceuticals的首席营运官，他领导着商业运作、制造业务、信息服务、项目与联盟管理和业务开发。他曾在King Pharmaceuticals担任过多个高级管理职务，其中包括神经科学部高级营销与销售副总裁、国际销售与营销副总裁、医院销售副总裁。他也曾供职于Medco Research的商业部门，该公司后来被King, COR Therapeutics（在那里他协助成功的推出依非巴特药物品牌INTEGRILIN）收购，还曾在B. Braun Interventional 和 BOC Group任职。他毕业于美国西点军校，获得了领导力学士学位，毕业之后他曾是一名美国陆军军官。
Richard W. Pascoe,has served as a director of Zevra Therapeutics, Inc. Company since January 2014 and Zevra Therapeutics, Inc. Company's Chief Executive Officer since January 2023. He served as Zevra Therapeutics, Inc. Company's executive chairman from November 2021 to January 2023. From January 2019 to November 2021, Mr. Pascoe served as the president and chief executive officer and on the board of directors of Histogen Inc., a biologics company. From March 2013 to January 2019, Mr. Pascoe was the chief executive officer and director of Apricus Biosciences. From August 2008 to March 2013, Mr. Pascoe was the president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company. Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where hewas most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc, a specialty pharmaceutical company. Mr. Pascoe received his B.S. degree from the United States Military Academy at West Point. - Richard W. Pascoe，Pharmaceuticals收购。加入Somaxon之前，他是新兴的肿瘤制药公司ARIAD Pharmaceuticals的首席营运官，他领导着商业运作、制造业务、信息服务、项目与联盟管理和业务开发。他曾在King Pharmaceuticals担任过多个高级管理职务，其中包括神经科学部高级营销与销售副总裁、国际销售与营销副总裁、医院销售副总裁。他也曾供职于Medco Research的商业部门，该公司后来被King, COR Therapeutics（在那里他协助成功的推出依非巴特药物品牌INTEGRILIN）收购，还曾在B. Braun Interventional 和 BOC Group任职。他毕业于美国西点军校，获得了领导力学士学位，毕业之后他曾是一名美国陆军军官。
- Richard W. Pascoe,has served as a director of Zevra Therapeutics, Inc. Company since January 2014 and Zevra Therapeutics, Inc. Company's Chief Executive Officer since January 2023. He served as Zevra Therapeutics, Inc. Company's executive chairman from November 2021 to January 2023. From January 2019 to November 2021, Mr. Pascoe served as the president and chief executive officer and on the board of directors of Histogen Inc., a biologics company. From March 2013 to January 2019, Mr. Pascoe was the chief executive officer and director of Apricus Biosciences. From August 2008 to March 2013, Mr. Pascoe was the president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company. Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where hewas most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc, a specialty pharmaceutical company. Mr. Pascoe received his B.S. degree from the United States Military Academy at West Point.
- Daniel J. O'Connor
-
Daniel J. O'Connor，2013年1月加入Advaxis公司担任高级副总裁、首席法律和业务发展官；于2013年5月晋升为执行副总裁；2013年8月，晋身为Advaxis公司的总裁兼首席执行官。O'Connor先生拥有十五年的在生物制药行业 （英克隆公司、PharmaNet公司和Bracco Diagnostics公司）的行政、法律和法规方面的经验。2003年加入英克隆公司。他支持ERBITUXR的临床开发、启动和商业化。作为英克隆公司的高级副总裁、总顾问和秘书，他在解决ImClone公司面临的问题中发挥重要作用，包括在2008年该公司被出售给美国礼来公司之前的广泛授权谈判。在加盟英克隆公司之前，他是PharmaNet公司的总顾问，帮助该公司从初创合同研究组织发展成一个临床研究领先者。奥康纳先生是新泽西州的刑事检察官，并于1990年担任波斯湾美海军陆战队上尉。最近，在Bracco Diagnostics（一家大型的私人制药和医疗设备公司），奥康纳先生担任该公司的副总裁兼总法律顾问。
Daniel J. O'Connor has served as our Chair and Chief Executive Officer since our inception. Between September 2017 and June 2021 Mr. O'Connor served as the Chief Executive Officer, President and Director of OncoSec Medical Incorporated, a NJ based biotech company an intratumoral cancer immunotherapy that utilizes IL-12. While CEO of OncoSec, Mr. O'Connor has launched two KEYNOTE studies combining Merck's Keytruda® in PD-1 checkpoint refractory metastatic melanoma and in late-stage chemo-refractory triple negative breast cancer, raised more than $150 million and in 2019 successfully coordinated a $30 million strategic financing and collaboration with well-established biopharma partners. Prior to OncoSec, Mr. O'Connor served as President and CEO of Advaxis Inc., where he successfully up-listed the company to NASDAQ, implemented a turnaround strategy that resulted in more than $300 million raised in funding and licensing deals and established major partnerships with companies such as Amgen Inc., Merck & Co. and Bristol Myers Squibb. Under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials and several PD-1 combination clinical studies with Keytruda® and Opdivo®, which ultimately transformed Advaxis into a patient-focused, leading cancer immunotherapy company. Earlier in his career, Mr. O'Connor was the General Counsel and Senior Vice President for ImClone Systems where he led the clinical development, launch and commercialization of ERBITUX®, and positioned ImClone for sale to Eli Lilly in 2008. Mr. O'Connor served as General Counsel at PharmaNet today, Syneos Health and was part of the senior leadership team that grew PharmaNet from a start-up clinical research organization (CRO) into a well-established leader in clinical research. Mr. O'Connor is a founding member the Board of Directors for Seelos Therapeutics (NASDAQ: SEEL) and is the Chairman of the Audit Committee. Mr. O'Connor was also a member of the Board of Trustees of BioNJ from 2015 to 2021 and previously served as its Vice Chairman and Chairman of its Nominating Committee for several years. In 2015 Ernst & Young named Mr. O'Connor Entrepreneur of the Year® in New Jersey. Also in 2015 he was the “Highly Commended” award winner for the 8th Vaccine Industry Excellence Award (ViE) Best Biotech CEO. In 2017 he was appointed by the governor of New Jersey to serve on the New Jersey Biotechnology Task Force. The Task Force was created to improve communication between State government and the industry to find ways to help retain and attract biotechnology companies to New Jersey. In 2018 he received Irish American Magazine Healthcare & Life Sciences 50 Honoree. In May, 2021 he was named a finalist for the Ernst & Young Entrepreneur of the Year® in New Jersey. He is a 1995 graduate of the Penn State University's Dickinson School of Law in Carlisle, Pennsylvania and previously served as a Trusted Advisor to its Dean. Mr. O'Connor graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as a Lieutenant in the U.S. Marines, attaining the rank of Captain and was deployed to Saudi Arabia for Operation Desert Shield. Prior to his career in drug development, Mr. O'Connor was a former criminal prosecutor in Somerset County, New Jersey. - Daniel J. O'Connor，2013年1月加入Advaxis公司担任高级副总裁、首席法律和业务发展官；于2013年5月晋升为执行副总裁；2013年8月，晋身为Advaxis公司的总裁兼首席执行官。O'Connor先生拥有十五年的在生物制药行业 （英克隆公司、PharmaNet公司和Bracco Diagnostics公司）的行政、法律和法规方面的经验。2003年加入英克隆公司。他支持ERBITUXR的临床开发、启动和商业化。作为英克隆公司的高级副总裁、总顾问和秘书，他在解决ImClone公司面临的问题中发挥重要作用，包括在2008年该公司被出售给美国礼来公司之前的广泛授权谈判。在加盟英克隆公司之前，他是PharmaNet公司的总顾问，帮助该公司从初创合同研究组织发展成一个临床研究领先者。奥康纳先生是新泽西州的刑事检察官，并于1990年担任波斯湾美海军陆战队上尉。最近，在Bracco Diagnostics（一家大型的私人制药和医疗设备公司），奥康纳先生担任该公司的副总裁兼总法律顾问。
- Daniel J. O'Connor has served as our Chair and Chief Executive Officer since our inception. Between September 2017 and June 2021 Mr. O'Connor served as the Chief Executive Officer, President and Director of OncoSec Medical Incorporated, a NJ based biotech company an intratumoral cancer immunotherapy that utilizes IL-12. While CEO of OncoSec, Mr. O'Connor has launched two KEYNOTE studies combining Merck's Keytruda® in PD-1 checkpoint refractory metastatic melanoma and in late-stage chemo-refractory triple negative breast cancer, raised more than $150 million and in 2019 successfully coordinated a $30 million strategic financing and collaboration with well-established biopharma partners. Prior to OncoSec, Mr. O'Connor served as President and CEO of Advaxis Inc., where he successfully up-listed the company to NASDAQ, implemented a turnaround strategy that resulted in more than $300 million raised in funding and licensing deals and established major partnerships with companies such as Amgen Inc., Merck & Co. and Bristol Myers Squibb. Under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials and several PD-1 combination clinical studies with Keytruda® and Opdivo®, which ultimately transformed Advaxis into a patient-focused, leading cancer immunotherapy company. Earlier in his career, Mr. O'Connor was the General Counsel and Senior Vice President for ImClone Systems where he led the clinical development, launch and commercialization of ERBITUX®, and positioned ImClone for sale to Eli Lilly in 2008. Mr. O'Connor served as General Counsel at PharmaNet today, Syneos Health and was part of the senior leadership team that grew PharmaNet from a start-up clinical research organization (CRO) into a well-established leader in clinical research. Mr. O'Connor is a founding member the Board of Directors for Seelos Therapeutics (NASDAQ: SEEL) and is the Chairman of the Audit Committee. Mr. O'Connor was also a member of the Board of Trustees of BioNJ from 2015 to 2021 and previously served as its Vice Chairman and Chairman of its Nominating Committee for several years. In 2015 Ernst & Young named Mr. O'Connor Entrepreneur of the Year® in New Jersey. Also in 2015 he was the “Highly Commended” award winner for the 8th Vaccine Industry Excellence Award (ViE) Best Biotech CEO. In 2017 he was appointed by the governor of New Jersey to serve on the New Jersey Biotechnology Task Force. The Task Force was created to improve communication between State government and the industry to find ways to help retain and attract biotechnology companies to New Jersey. In 2018 he received Irish American Magazine Healthcare & Life Sciences 50 Honoree. In May, 2021 he was named a finalist for the Ernst & Young Entrepreneur of the Year® in New Jersey. He is a 1995 graduate of the Penn State University's Dickinson School of Law in Carlisle, Pennsylvania and previously served as a Trusted Advisor to its Dean. Mr. O'Connor graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as a Lieutenant in the U.S. Marines, attaining the rank of Captain and was deployed to Saudi Arabia for Operation Desert Shield. Prior to his career in drug development, Mr. O'Connor was a former criminal prosecutor in Somerset County, New Jersey.
- Brian Lian
-
Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College. - Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
- Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.
高管简历
中英对照 | 中文 | 英文- Raj Mehra
Raj Mehra自2019年1月以来一直担任我们的总裁，首席执行官，临时首席财务官和董事会主席。在创立Seelos之前，Mehra博士在Auriga USA，LLC工作了9年，担任总经理，专注于全球梦百合公司的私人和公共股本投资。在加入Auriga之前，Mehra博士是纽约Bennett Lawrence Management，LLC的梦百合股票投资部门主管。他也曾创立并管理Weiss，Peck&Greer LLC的多空股票对冲基金。Mehra博士在Cowen Asset Management，LLC担任投资专业人员开始他的职业生涯。Mehra博士拥有纽约哥伦比亚大学（Columbia University）的M.S.，M.Phil.，博士，法学博士和工商管理硕士学位。他也是印度理工学院坎普尔分校（Indian Institute of Technology，Kanpur）的毕业生，在那里他在班上排名第一。
Raj Mehra has served on our board of directors since July 2021. Dr. Mehra has served as Seelos Therapeutics's President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board of Directors since January 2019. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC as a Managing Director focused on private and public equity investments in global healthcare companies. Prior to Auriga, Dr. Mehra was the sector head for healthcare equity investments at Bennett Lawrence Management, LLC in New York. He also founded and managed a long-short equity hedge fund at Weiss, Peck & Greer LLC. Dr. Mehra started his career as an investment professional at Cowen Asset Management, LLC. Dr. Mehra holds M.S., M.Phil., Ph.D., JD and MBA degrees from Columbia University in New York. He is also a graduate of Indian Institute of Technology, Kanpur, where he was ranked first in his class.- Raj Mehra自2019年1月以来一直担任我们的总裁，首席执行官，临时首席财务官和董事会主席。在创立Seelos之前，Mehra博士在Auriga USA，LLC工作了9年，担任总经理，专注于全球梦百合公司的私人和公共股本投资。在加入Auriga之前，Mehra博士是纽约Bennett Lawrence Management，LLC的梦百合股票投资部门主管。他也曾创立并管理Weiss，Peck&Greer LLC的多空股票对冲基金。Mehra博士在Cowen Asset Management，LLC担任投资专业人员开始他的职业生涯。Mehra博士拥有纽约哥伦比亚大学（Columbia University）的M.S.，M.Phil.，博士，法学博士和工商管理硕士学位。他也是印度理工学院坎普尔分校（Indian Institute of Technology，Kanpur）的毕业生，在那里他在班上排名第一。
- Raj Mehra has served on our board of directors since July 2021. Dr. Mehra has served as Seelos Therapeutics's President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board of Directors since January 2019. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC as a Managing Director focused on private and public equity investments in global healthcare companies. Prior to Auriga, Dr. Mehra was the sector head for healthcare equity investments at Bennett Lawrence Management, LLC in New York. He also founded and managed a long-short equity hedge fund at Weiss, Peck & Greer LLC. Dr. Mehra started his career as an investment professional at Cowen Asset Management, LLC. Dr. Mehra holds M.S., M.Phil., Ph.D., JD and MBA degrees from Columbia University in New York. He is also a graduate of Indian Institute of Technology, Kanpur, where he was ranked first in his class.